First-line treatment of prolactinoma is usually medical, based on dopamine agonists receptors, mainly cabergoline. The classical side-effects of cabergoline (low blood pressure and nausea) have been well known since it was first introduced. Other side-effects, however, are more controversial or simply less frequent, but need to be considered during monitoring. This review will focus on these side-effects: cardiac valvular fibrosis, pleural, pericardial and retroperitoneal fibrosis, addictive/compulsive behaviors, and risks secondary to significantly decreased tumor volume. We will also describe how such side-effects should be monitored and managed. In our opinion, the low prevalence of these side-effects should not cast doubt on the role of cabergoline in the therapeutic algorithm of prolactinoma.

泌乳素瘤的一线治疗通常是药物治疗，基于多巴胺激动剂受体，主要是卡麦角林。卡麦角林的经典副作用（低血压和恶心）自首次推出以来就广为人知。然而，其他副作用更具争议性或频率较低，但需要在监测期间加以考虑。本综述将重点关注这些副作用：心脏瓣膜纤维化、胸膜、心包和腹膜后纤维化、成瘾/强迫行为以及肿瘤体积显着减少的继发风险。我们还将描述应如何监控和管理此类副作用。我们认为，这些副作用的低发生率不应让人怀疑卡麦角林在催乳素瘤治疗方法中的作用。